Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Southwest Oncology Group
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01809691
First received: March 8, 2013
Last updated: December 8, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2020 (Final data collection date for primary outcome measure)